GLS 5700

Drug Profile

GLS 5700

Alternative Names: GLS-5700; Zika dMAb® therapy

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator GeneOne Life Science; Inovio Pharmaceuticals
  • Class DNA vaccines; Monoclonal antibodies; Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 15 Mar 2017 Immunogenicity data from phase I tria in Zika virus infections released by Inovio Pharmaceuticals
  • 01 Nov 2016 GeneOne Life Science and Inovio Pharmaceuticals complete a phase I trial for Zika virus infections in USA and Canada (NCT02809443)
  • 29 Aug 2016 Phase-I clinical trials in Zika virus infection (In volunteers, Prevention) in Puerto Rico (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top